Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.

Ying Fu, Jun Li, Mingxuan Feng, Xiaomei Yang, Yahui Wang, Yanli Zhang, Wenxin Qin, Qiang Xia, Zhigang ZhangPubMed 2014

TL;DR

This study identifies cytohesin-3 as a protein significantly upregulated in hepatocellular carcinoma (HCC) tissues. Its elevated levels correlate with poorer patient survival and are linked to tumor size and vascular invasion, suggesting cytohesin-3 as a potential prognostic marker and therapeutic target for HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a deadly cancer with a high rate of recurrence and metastasis, making its prognosis poor despite current treatments. The lack of effective targeted therapies highlights the urgent need to identify new molecular targets that drive HCC progression and metastasis. While other cytohesins have been implicated in cancer, the specific role of cytohesin-3 in HCC remained largely unexplored, presenting a knowledge gap in understanding HCC pathogenesis and potential therapeutic avenues.

Methods

The researchers employed a multi-pronged approach to investigate cytohesin-3's role in HCC:

  • Quantitative Real-Time PCR (qRT-PCR) and Western Blotting: These standard molecular biology techniques were used to measure the expression levels of cytohesin-3 mRNA and protein in paired HCC and non-tumor liver tissues. This allowed for the initial assessment of whether cytohesin-3 is differentially expressed in cancerous tissue.
  • Immunohistochemistry (IHC): This technique was used to visualize and quantify cytohesin-3 protein expression in a larger cohort of HCC tissue microarrays (TMAs). This enabled the correlation of protein levels with clinicopathological features and patient outcomes.
  • Clinicopathological Correlation and Survival Analysis: Statistical methods, including Pearson's chi-squared test and Kaplan-Meier survival analysis, were used to determine the relationship between cytohesin-3 expression levels and various patient characteristics (age, gender, tumor size, vascular invasion, etc.) and their overall survival (OS) and relapse-free survival (RFS).
  • Small Interfering RNA (siRNA) Transfection: This molecular technique was used to specifically reduce the expression of cytohesin-3 in HCC cell lines. This allowed the researchers to investigate the functional consequences of cytohesin-3 depletion.
  • Cell Proliferation Assay (CCK-8): This assay measures cell viability and proliferation by quantifying the metabolic activity of cells. It was used to assess the impact of cytohesin-3 knockdown on HCC cell growth.
  • In Vitro Migration Assay (Transwell): This assay is used to evaluate the migratory capacity of cells. It was employed to determine if reducing cytohesin-3 levels affects the ability of HCC cells to move.

Datasets

  • Paired HCC and Non-tumor Liver Tissues: Used for initial qRT-PCR and Western blot analysis (18 pairs for qRT-PCR, 14 pairs for Western blot).
  • HCC Tissue Microarrays (TMAs): A larger dataset of 202 HCC samples collected between 2004 and 2010 was used for immunohistochemical staining and subsequent clinicopathological correlation and survival analysis.
  • HCC Cell Lines: Multiple HCC cell lines (e.g., MHCC-97H, Hep3B, HepG2, SK-Hep1) and two non-HCC cell lines (LX2, LO2) were used for Western blotting, qRT-PCR, and functional assays (proliferation and migration).

Key Insights and Ideas

  • Cytohesin-3 as a "Red Flag" for HCC: The consistent upregulation of cytohesin-3 in HCC tissues, compared to normal liver tissue, immediately flags it as a potential driver or marker of the disease.
  • Prognostic Power Beyond Simple Presence: The correlation of high cytohesin-3 expression with worse patient survival (both overall and relapse-free) is a critical finding. This suggests it's not just a bystander but actively contributes to a more aggressive disease course.
  • Link to Aggressive Phenotypes: The association of high cytohesin-3 with larger tumor size and, crucially, vascular invasion, points towards its role in promoting tumor growth and the critical process of metastasis.
  • Functional Role in Proliferation and Migration: The in vitro experiments demonstrating that reducing cytohesin-3 levels impairs HCC cell proliferation and migration provide direct evidence for its functional contribution to these aggressive behaviors. This bridges the gap between observation and mechanism.

Key Results

  • Upregulation: Cytohesin-3 mRNA and protein levels were significantly higher in HCC tissues compared to non-tumor liver tissues (Figure 1).
  • Prevalence: Cytohesin-3 was upregulated in 60.71% of HCC patients analyzed by IHC.
  • Clinical Correlations: High cytohesin-3 expression was significantly correlated with larger tumor size (P=0.041) and vascular invasion (P=0.006) (Table 1).
  • Survival Impact: Patients with high cytohesin-3 expression had significantly lower overall survival (OS) (P=0.002) and relapse-free survival (RFS) (P=0.002) (Figure 2).
  • Functional Inhibition: Knockdown of cytohesin-3 using siRNA significantly suppressed HCC cell proliferation (Figure 4) and migration (Figure 5) in MHCC-97H and Hep3B cell lines.

Limitations and Future Work

  • Tissue Specificity: The authors acknowledge that the functions of cytohesins can be tissue-specific or microenvironment-dependent, suggesting that further studies are needed to fully elucidate cytohesin-3's precise mechanisms in HCC.
  • Mechanism of Action: While the study demonstrates that cytohesin-3 contributes to proliferation and migration, the detailed molecular pathways and interactions through which it exerts these effects are not fully elucidated. Future work could focus on identifying the specific signaling cascades and protein interactions involved.
  • Therapeutic Potential: The study suggests cytohesin-3 as a potential therapeutic target. Further research would be needed to develop and test specific inhibitors of cytohesin-3 for their efficacy in preclinical models and eventually in clinical trials.
  • Broader Malignant Tumors: The authors propose that cytohesin-3's role in HCC might extend to other malignant tumors, suggesting it as a candidate for further investigation in different cancer types.

Summary updated

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality, and is characterized by high potential for metastasis and recurrence. The outcome of it is still poor due to lacking of targeted therapeutic strategies. There is an urgent need to find new therapeutic targets for interventions against HCC metastasis and recurrence. In the present study, we found cytohesin-3, a member of the cytohesin family, was upregulated in HCC tissues, and its expression was negatively correlated with the overall survival and relapse-free survival of HCC patients. Further clinicopathological correlation analysis revealed that cytohesin-3 expression was related with tumor size and vascular invasion. And in vitro studies revealed that knock-down of cytohesin-3 suppressed HCC cells proliferation and migration. These results suggest that cytohesin-3 may act as a novel prognostic factor of HCC, and it might also be useful to exploit targeted therapeutic drugs against HCC growth and metastasis.
BibTeX
@inproceedings{fu2014cytohesin,
  author = {Ying Fu and Jun Li and Mingxuan Feng and Xiaomei Yang and Yahui Wang and Yanli Zhang and Wenxin Qin and Qiang Xia and Zhigang Zhang},
  title = {{Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.}},
  booktitle = {PubMed},
  year = {2014},
}
Figure